Search results
Showing 6361 to 6375 of 9026 results
NICE appoints Dr Adrian Hayter as its new chief medical officer
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following the successful negotiation of a commercial deal to make the medicine available on the NHS.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
Neonatal infection guidance updated to allow home antibiotic treatment for some babies
We’ve recommended that newborn babies receiving antibiotics in hospital could potentially switch to oral antibiotics and be cared for at home if they are doing well and responding to treatment.
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final draft guidance today.
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
The targeted treatment helps people live longer and can help prevent the disease from returning.
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Home News Podcasts Backing the healthtech that changes lives Podcasts 31 March 2026 Listen About this episode When the right technology reaches
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151.
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Weight management: BMI calculation in preceding 5 years (IND167)
This indicator has been withdrawn following discussions with the National Screening Committee.
This guidance has been updated and replaced by NICE indicator 277.